

NEWS RELEASE

Uroplasty, Inc. Reports Financial Results for the First Quarter Ended June 30, 2007

-- First Fiscal Quarter Sales up 67% --

MINNEAPOLIS, MN, August 13, 2007 – Uroplasty, Inc. (AMEX: UPI) today reported record sales of \$2.9 million for the first quarter of fiscal 2008 ended June 30, 2007, up 67%, or approximately \$1.2 million, from \$1.8 million for the same quarter in the prior year. Excluding the impact of fluctuations in foreign currency exchange rates, sales increased by approximately 62%. Approximately three-fourths of the \$1.2 million sales increase is attributed to the growth in sales to customers in the U.S.

Sales to customers in the U.S. continued to show sequential, quarter-to-quarter growth. Sales in the fiscal 2008 quarter were \$1.0 million, up from \$705,000, an increase of 42% over the previous quarter, and up from \$103,000 in the year ago quarter.

Net loss for the fiscal 2008 quarter was \$841,000, or \$0.06 per diluted share, compared to a net loss for the same quarter in the prior year of \$1.2 million, or \$0.18 per diluted share.

David B. Kaysen, Uroplasty's President and CEO said, "We recorded growth in all our geographic areas. Our business outside of the United States grew on the strength of our Macroplastique® and Urgent PC® products. In the U.S., we believe our sales force reorganization and increased product awareness by our customers enhanced sales growth. We have now scaled back to a smaller group of more productive independent sales agents supplemented by an expanded company-employed field sales force of seven people. We are currently evaluating further expansion of our company-employed field sales force."

Kaysen added, "Last May we exhibited our products at the American Urological Association's annual convention in Anaheim, California, attended by physicians from throughout the world. We were very pleased with the favorable response from the physicians to our products, led by the Urgent PC, suggesting increased customer awareness of our products."

As previously announced, Uroplasty will host an audio conference call on August 13, 2007, at 2:00 pm central time to review the financial results for the first fiscal quarter. David Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer will host the call. Listeners wishing to participate in the conference call should call toll free at 1-888-321-3075. The conference call ID number is 911-1397. A digital recording at toll free telephone number 1-877-519-4471 (ID number 911-1397) will be available starting about two hours after the completion of the conference call through September 12, 2007.

UROPLASTY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2007 (unaudited)	March 31, 2007
Assets		
Total current assets	\$8,590,781	\$9,212,783
Property, plant, and equipment, net	1,459,165	1,431,749
Intangible assets, net	4,845,177	308,093
Deferred tax assets	94,234	93,819
	\$14,989,357	\$11,046,444
 Liabilities and Shareholders' Equity		
Total current liabilities	\$1,529,271	\$2,005,608
Long-term debt – less current maturities	411,935	427,382
Deferred rent – less current portion	206,030	214,381
Accrued pension liability	458,937	596,026
	\$2,606,173	\$3,243,397
Total liabilities	\$2,606,173	\$3,243,397
Total shareholders' equity	\$12,383,184	\$7,803,047
Total liabilities and shareholders' equity	\$14,989,357	\$11,046,444

UROPLASTY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended	
	June 30,	
	<u>2007</u>	<u>2006</u>
Net sales	\$2,948,674	\$1,764,210
Cost of goods sold	594,212	555,516
	<hr/>	<hr/>
Gross profit	2,354,462	1,208,694
	<hr/>	<hr/>
Operating expenses		
General and administrative	808,374	857,572
Research and development	506,125	674,954
Selling and marketing	1,632,789	1,232,587
Amortization of intangibles	216,521	26,537
	<hr/>	<hr/>
	3,163,809	2,791,650
	<hr/>	<hr/>
Operating loss	(809,347)	(1,582,956)
	<hr/>	<hr/>
Other income (expense)		
Interest income	76,383	19,507
Interest expense	(11,365)	(5,982)
Warrant benefit	-	327,732
Foreign currency exchange gain (loss)	(2,029)	26,411
Other, net	1,879	4,800
	<hr/>	<hr/>
	64,868	372,468
	<hr/>	<hr/>
Loss before income taxes	(744,479)	(1,210,488)
	<hr/>	<hr/>
Income tax expense	96,156	30,751
	<hr/>	<hr/>
Net loss	\$(840,635)	\$(1,241,239)
	<hr/> <hr/>	<hr/> <hr/>
Basic and diluted loss per common share	\$(0.06)	\$(0.18)
Weighted average common shares outstanding:		
Basic and diluted	12,981,466	6,952,167

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, overactive bladder and vesicoureteral reflux.

The Urgent® PC Neuromodulation System is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of overactive bladder. Uroplasty sells the Urgent PC system in the United States, in Canada and in countries recognizing the CE mark. Outside the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.

The I-STOP™ Mid-Urethral Sling is a biocompatible, tension-free sling used to treat female stress urinary incontinence. The I-STOP sling provides a hammock-like support for the urethra to prevent urine leakage associated with activities such as coughing, laughing, lifting or jumping. Uroplasty sells the I-STOP Sling in the United Kingdom.

Macroplastique® Implants, Uroplasty's patented soft tissue bulking agent, is used to treat both female and male urinary incontinence and to treat vesicoureteral reflux in children. When Macroplastique is injected into tissue, it stabilizes and "bulks" the tissue, providing the surrounding muscles with increased capability to control the flow of urine. Additionally, Uroplasty markets soft tissue bulking agents for specific indications such as PTQ™ Implants for the treatment of fecal incontinence, VOX® Implants for the treatment of vocal cord rehabilitation and Bioplastique® for augmentation or restoration of soft tissue defects in plastic surgery indications. Uroplasty sells Macroplastique in the United States and in countries throughout the world. Uroplasty sells its other bulking products outside the United States.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words "aim," "believe," "expect," "anticipate," "intend," "estimate" and other expressions, which indicate future events and trends, identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently introduced product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. Our financial performance for the fiscal 2008 quarter is not indicative of future performance. In particular, we cannot assure that we will achieve our projected revenue target range for fiscal 2008 or that we can successfully expand our U.S. field sales force. Uroplasty undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

FOR FURTHER INFORMATION: visit Uroplasty's web page at www.uroplasty.com or contact David Kaysen, President and CEO or Medi Jiwani, Vice President, CFO and Treasurer.

UROPLASTY, INC.
5420 Feltl Road
Minnetonka, Minnesota 55343
Tel: 952.426.6140
Fax: 952.426.6199